Bimekizumab Cumulative Clinical Benefit in Patients With Moderate to Severe Hidradenitis Suppurativa through 1 Year of the BE HEARD I&II Phase 3 Trials. J of Skin 2024, 8 (6), s477. https://doi.org/10.25251/skin.8.supp.477.